DK0894129T3 - Korte ydre styresekvenser - Google Patents

Korte ydre styresekvenser

Info

Publication number
DK0894129T3
DK0894129T3 DK97915007T DK97915007T DK0894129T3 DK 0894129 T3 DK0894129 T3 DK 0894129T3 DK 97915007 T DK97915007 T DK 97915007T DK 97915007 T DK97915007 T DK 97915007T DK 0894129 T3 DK0894129 T3 DK 0894129T3
Authority
DK
Denmark
Prior art keywords
molecules
rnase
segs
target
stem
Prior art date
Application number
DK97915007T
Other languages
English (en)
Inventor
Martina Werner
Michael Ma
Shaji T George
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK0894129T3 publication Critical patent/DK0894129T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Seal Device For Vehicle (AREA)
  • Saccharide Compounds (AREA)
  • Pens And Brushes (AREA)
DK97915007T 1996-03-14 1997-03-14 Korte ydre styresekvenser DK0894129T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/615,961 US5877162A (en) 1996-03-14 1996-03-14 Short external guide sequences

Publications (1)

Publication Number Publication Date
DK0894129T3 true DK0894129T3 (da) 2004-09-27

Family

ID=24467475

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97915007T DK0894129T3 (da) 1996-03-14 1997-03-14 Korte ydre styresekvenser

Country Status (9)

Country Link
US (1) US5877162A (da)
EP (1) EP0894129B1 (da)
JP (1) JP4062365B2 (da)
AT (1) ATE267866T1 (da)
AU (1) AU2206197A (da)
DE (1) DE69729292T2 (da)
DK (1) DK0894129T3 (da)
ES (1) ES2221955T3 (da)
WO (1) WO1997033991A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) * 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
JP2001519141A (ja) * 1997-10-07 2001-10-23 スミスクライン・ビーチャム・コーポレイション 遺伝子発現の調節方法
WO1999027135A2 (en) * 1997-11-21 1999-06-03 Yale University Method for identifying and inhibiting functional nucleic acid molecules in cells
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
DE19853665B4 (de) 1998-11-20 2005-06-30 Siemens Ag Fahrzeugkommunikationssystem und Verfahren zum Austausch von Daten in einem Kraftfahrzeug
WO2000061810A1 (en) * 1999-04-08 2000-10-19 Oasis Biosciences, Inc. Antisense oligonucleotides comprising universal and/or degenerate bases
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
AU9684601A (en) 2000-10-12 2002-04-22 Univ Rochester Compositions that inhibit proliferation of cancer cells
US7811992B2 (en) 2002-02-06 2010-10-12 Stasys Technologies, Inc. Anti-infarction molecules
EP1534729A2 (en) * 2002-02-26 2005-06-01 University of Utah Research Foundation Variants of nedd4l associated with hypertension and viral budding
EP2116604A1 (en) 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
CN1780920B (zh) * 2003-05-12 2012-03-28 波多玛克制药有限公司 基因表达抑制剂
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2284268A3 (en) * 2003-06-12 2012-05-30 Alnylam Pharmaceuticals Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2005021751A1 (en) * 2003-09-01 2005-03-10 Patrick Arbuthnot A self-processing rna expression cassette
DE60330160D1 (de) * 2003-12-16 2009-12-31 Bio Rad Pasteur Oligonukleotide zur Detektion von Hepatitis B Viren
PL1858916T4 (pl) 2005-03-15 2015-04-30 Fujirebio Europe N V Warianty wirusa zapalenia wątroby typu b z obniżoną wrażliwością na analogi nukleozydów i ich zastosowanie
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
EP1934244A2 (en) * 2005-10-06 2008-06-25 Emthrax LLC Methods and compositions relating to anthrax spore glycoproteins as vaccines
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP2395076A1 (en) 2005-10-14 2011-12-14 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
EP3034083B1 (en) 2006-09-21 2020-12-09 University of Rochester Antisense oligonucleotides for use in treating myotonic dystrophy
EP2104516B1 (en) 2006-11-01 2015-01-07 University of Rochester Methods and compositions related to the structure and function of apobec3g
CN101600451A (zh) 2006-12-11 2009-12-09 犹他大学研究基金会 用于治疗病理性血管生成和血管通透性的组合物和方法
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2706317C (en) * 2007-12-03 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Doc1 compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
CA2719923A1 (en) * 2008-04-08 2009-10-15 Amyris Biotechnologies, Inc. Expression of heterologous sequences
WO2009137686A1 (en) 2008-05-08 2009-11-12 University Of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
WO2010074924A1 (en) 2008-12-23 2010-07-01 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
MX2011008297A (es) * 2009-02-06 2012-01-25 Univ Berlin Freie Composicion farmaceutica para el tratamiento de efectos secundarios mediante la administracion de espiegelmeros.
CN101634047A (zh) * 2009-08-12 2010-01-27 广州金琪基因技术研究发展中心 一种外指引序列文库筛选方法
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
EP3266873A1 (en) 2010-11-10 2018-01-10 Nigel L. Webb Nuclions and ribocapsids
CN103608680A (zh) 2010-12-14 2014-02-26 詹姆士·W·里拉尔德 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
BR112017008696A2 (pt) 2014-10-27 2017-12-26 Univ Central Florida Res Found Inc métodos e composições para células exterminadoras naturais
SG11201703638XA (en) 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
AU2017306422A1 (en) 2016-08-03 2019-01-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
WO2019051355A1 (en) 2017-09-08 2019-03-14 Ohio State Innovation Foundation NEW MICROARN INHIBITOR THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS
MA70658B1 (fr) 2018-08-13 2026-04-30 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation
US12492245B2 (en) 2021-09-21 2025-12-09 University Of South Carolina Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104466A (en) * 1974-03-13 1978-08-01 Eishun Tsuchida Polymeric metal complex and method of manufacturing the same
IL69720A (en) * 1983-09-14 1987-08-31 Univ Ramot Anti-tumor pharmaceutical compositions comprising liposome-bound porphyrins
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU6131086A (en) * 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
GB2213684A (en) * 1987-12-11 1989-08-16 Philips Electronic Associated Data demodulator baud clock phase locking
AU632993B2 (en) * 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
EP0400047B1 (en) * 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5168053A (en) * 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
AU659482B2 (en) * 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
DK0638121T3 (da) * 1992-04-28 1996-08-12 Univ Yale Målrettet spaltning af RNA under anvendelse af eukaryotisk ribonuklease P og ekstern ledersekvens
WO1994013791A1 (en) * 1992-12-04 1994-06-23 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
JP3595841B2 (ja) * 1992-12-04 2004-12-02 サーナ セラピューティクス，インコーポレイテッド リボザイム増幅診断用薬
US6012375A (en) * 1993-07-06 2000-01-11 Eckstein; Donald B. Aircraft infrared guided defense missile system
EP0746614A1 (en) * 1994-02-23 1996-12-11 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
WO1996018733A2 (en) * 1994-12-14 1996-06-20 Innovir Laboratories, Inc. Ribozyme-mediated inactivation of leukemia-associated rna

Also Published As

Publication number Publication date
WO1997033991A1 (en) 1997-09-18
EP0894129A1 (en) 1999-02-03
US5877162A (en) 1999-03-02
DE69729292T2 (de) 2005-06-02
AU2206197A (en) 1997-10-01
ATE267866T1 (de) 2004-06-15
JP2000506731A (ja) 2000-06-06
JP4062365B2 (ja) 2008-03-19
EP0894129B1 (en) 2004-05-26
DE69729292D1 (de) 2004-07-01
ES2221955T3 (es) 2005-01-16

Similar Documents

Publication Publication Date Title
ATE267866T1 (de) Kurze externe führungssequenzen
ATE465168T1 (de) Xylo-lna analoge
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
Beaudry et al. An efficient strategy for the synthesis of circular RNA molecules
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
EP1765414A4 (en) ANTISENSE OLIGOMER COMPOUND WITH PEPTIDE-CONJUGATED INOSIN SUBSTITUTION, AND METHOD THEREFOR
EP1185546A4 (en) HIGHLY SPECIFIC PRIMERS, EXPRESSION PROCEDURES AND "KIT"
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
DK1546174T3 (da) Fremgangsmåder og sammensætninger til RNA-interferens
WO2004027035A3 (en) Riboswitches, methods for their use, and compositions for use with riboswitches.
MXPA05001355A (es) Formas nuevas adicionales de moleculas de arn de interferencia.
EP1417351A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A)
BR9910455A (pt) Processos e composições para expressão detransgenes em plantas
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
BR0115269A (pt) Processo para preparar uma composição fertilizante e melhoradora de solo, composição fertilizante e melhoradora de solo, e, método agrìcola ou horticultural
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
Carriero et al. Template-mediated synthesis of lariat RNA and DNA
WO2003027290A1 (fr) Procede pour conferer ou reguler la fertilite d'un cytoplasme a sterilite male de riz bt au moyen d'un gene de restauration de la fertilite, et procede d'estimation de la presence d'un gene de restauration de la fertilite
DE50110723D1 (de) Isolierte luziferasen sowie deren verwendung
AUPS333902A0 (en) Method of producing plants having enhanced transpiration efficiency and plants produced therefrom i
WO2004021978A3 (en) Antisense modulation of endothelial specific molecule 1 expression
ATE310823T1 (de) Expressionssystem zur produktion von proteinen in pilzen
WO2003050247A3 (en) Antisense modulation of mhc class ii transactivator expression
ATE500840T1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort